1型糖尿病中胰高血糖素样肽-1受体激动剂与钠-葡萄糖协同转运蛋白2抑制剂的临床与安全性结局:一项真实世界研究
本回顾性图表综述在单中心成人1型糖尿病患者中评估GLP-1RA和/或SGLT2i使用超过90天的临床与安全性结局。治疗1年后,GLP-1RA组体重、HbA1c和每日胰岛素总量显著下降,SGLT2i组HbA1c和基础胰岛素显著下降;GLP-1RA组体重降幅大于SGLT2i组,两组HbA1c降幅相当。平均使用29.5个月期间,SGLT2i组糖尿病酮症酸中毒发生率高于GLP-1RA组(12.8% vs 3.9%)。
要点
- GLP-1RA治疗1年后体重、HbA1c和每日胰岛素总量显著下降。
- SGLT2i治疗1年后HbA1c和基础胰岛素显著下降。
- SGLT2i组糖尿病酮症酸中毒发生率高于GLP-1RA组(12.8% vs 3.9%)。
核心结论
- GLP-1RA和SGLT2i用于1型糖尿病与临床相关获益相关,但SGLT2i使用中糖尿病酮症酸中毒仍是临床关注问题,需仔细选择患者和监测,并在个体水平评估治疗的风险获益比。
研究设计与样本
- 回顾性图表综述,纳入单中心成人1型糖尿病患者中所有使用GLP-1RA和/或SGLT2i超过90天的病例。
- 共识别104例1型糖尿病患者,其中76例使用GLP-1RA、39例使用SGLT2i超过90天。
主要发现
- GLP-1RA组治疗1年后体重从90.5 kg降至85.4 kg(P < .001),HbA1c从7.7%降至7.3%(P = .007),每日胰岛素总量从61.8单位降至41.9单位(P < .001)。
- SGLT2i组治疗1年后HbA1c从7.9%降至7.3%(P < .001),基础胰岛素从31.3单位降至25.6单位(P = .003)。
- GLP-1RA组较SGLT2i组体重降幅更大(P = .027),两组HbA1c降幅相当。
- 两组平均总使用时长29.5个月/患者期间,SGLT2i组糖尿病酮症酸中毒发生率高于GLP-1RA组(12.8% vs 3.9%)。
- 因不良事件停药的比例:GLP-1RA组26.9%,SGLT2i组27.7%。
临床怎么用
- 作者认为GLP-1RA和SGLT2i用于1型糖尿病与临床相关获益相关,SGLT2i使用中糖尿病酮症酸中毒仍是临床关注问题,需仔细选择患者和监测,并在个体水平评估治疗的风险获益比。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) are used off-label in the management of type 1 diabetes mellitus (T1DM) in real-world practice as adjuvant therapies to insulin. There are few real-world data regarding efficacy and safety of this practice. OBJECTIVE: This work aimed to determine the efficacy and safety of GLP-1RAs and sodium-glucose SGLT2is in the management of T1DM in real-world practice. METHODS: A retrospective chart review was performed of all instances of GLP-1RA and/or SGLT2i use greater than 90 days in adult patients with T1DM at a single academic center. We report the clinical and safety outcomes over the duration of use. RESULTS: We identified 104 patients with T1DM who ever used a GLP-1RA (76 patients) or SGLT2i (39 patients) for more than 90 days. After 1 year of therapy, GLP-1RA users had statistically significant reductions in weight (90.5 kg to 85.4 kg; P < .001), glycated hemoglobin A1c (HbA1c) (7.7% to 7.3%; P = .007), and total daily dose of insulin (61.8 units to 41.9 units; P < .001). SGLT2i users had statistically significant reductions in HbA1c (7.9% to 7.3%; P < .001) and basal insulin (31.3 units to 25.6 units; P = .003). GLP-1RA users compared to SGLT2i users had greater reduction in weight (P = .027) while HbA1c reduction was comparable between the groups. Over a mean total duration of use of 29.5 months/patient for both groups, more SGLT2i users experienced diabetic ketoacidosis (DKA) (12.8% vs 3.9%). Therapy was discontinued because of adverse events 26.9% of the time for GLP-1RA users vs 27.7% for SGLT2i users. CONCLUSION: GLP-1RA and SGLT2i use in T1DM is associated with clinically relevant benefits. DKA remains a clinical concern with SGLT2i use, requiring careful patient selection and monitoring, with the risk to benefit ratio of treatment evaluated at an individual level.
引用
- Edwards K, Li X, Lingvay I, et al. Clinical and Safety Outcomes With GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 1 Diabetes: A Real-World Study. J Clin Endocrinol Metab. 2023. PMID: 36268825. doi:10.1210/clinem/dgac618
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。